pyrroles has been researched along with Plasmacytoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, KC; Chauhan, D; Lloyd, GK; Palladino, MA; Potts, BC; Singh, AV | 1 |
| Anderson, KC; Berkers, C; Catley, L; Chao, TH; Chauhan, D; Hideshima, T; Letai, A; Li, G; Mitsiades, C; Mitsiades, N; Neuteboom, ST; Nicholson, B; Ovaa, H; Palladino, MA; Podar, K; Richardson, P; Velankar, M; Yasui, H | 1 |
2 other study(ies) available for pyrroles and Plasmacytoma
| Article | Year |
|---|---|
Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model.
Topics: Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Kidney; Lactones; Male; Mice; Plasmacytoma; Proteasome Inhibitors; Pyrroles; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Movement; Cell Proliferation; Drug Synergism; Genes, bcl-2; Humans; Lactones; Lymphocytes; Mice; Mitochondria; Multiple Myeloma; NF-kappa B; Plasmacytoma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Pyrroles; Tumor Cells, Cultured | 2005 |